Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.

Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, Neuberg DS, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V.

Cancer Discov. 2018 Jul;8(7):884-897. doi: 10.1158/2159-8290.CD-17-0912. Epub 2018 Jun 13.

2.

Cdk6: At the interface of Rb and p53.

Nebenfuehr S, Bellutti F, Sexl V.

Mol Cell Oncol. 2018 Sep 5;5(5):e1511206. doi: 10.1080/23723556.2018.1511206. eCollection 2018.

3.
4.

EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.

Kapoor GS, Christie A, O'Rourke DM.

Cancer Biol Ther. 2007 Apr;6(4):571-9.

PMID:
17457042
5.

Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.

Rodríguez-Díez E, Quereda V, Bellutti F, Prchal-Murphy M, Partida D, Eguren M, Kollmann K, Gómez de Cedrón M, Dubus P, Cañamero M, Martínez D, Sexl V, Malumbres M.

Blood. 2014 Oct 9;124(15):2380-90. doi: 10.1182/blood-2014-02-555292. Epub 2014 Aug 25.

PMID:
25157181
6.

Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation.

Ito K, Maruyama Z, Sakai A, Izumi S, Moriishi T, Yoshida CA, Miyazaki T, Komori H, Takada K, Kawaguchi H, Komori T.

Oncogene. 2014 Apr 3;33(14):1862-71. doi: 10.1038/onc.2013.130. Epub 2013 Apr 29.

PMID:
23624920
7.

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.

Esfandiari A, Hawthorne TA, Nakjang S, Lunec J.

Mol Cancer Ther. 2016 Mar;15(3):379-91. doi: 10.1158/1535-7163.MCT-15-0651. Epub 2016 Feb 1.

8.
9.

Transformation of normal human fibroblasts into immortalized cells with the mutant p53 gene and X-rays.

Fushimi K, Iijima M, Gao C, Kondo T, Tsuji T, Hashimoto T, Mihara K, Namba M.

Int J Cancer. 1997 Jan 6;70(1):135-40.

10.

Preclinical effects of honokiol on treating glioblastoma multiforme via G1 phase arrest and cell apoptosis.

Lin CJ, Chang YA, Lin YL, Liu SH, Chang CK, Chen RM.

Phytomedicine. 2016 May 15;23(5):517-27. doi: 10.1016/j.phymed.2016.02.021. Epub 2016 Mar 9.

PMID:
27064011
11.

A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

Loizou E, Banito A, Livshits G, Ho YJ, Koche RP, Sánchez-Rivera FJ, Mayle A, Chen CC, Kinalis S, Bagger FO, Kastenhuber ER, Durham BH, Lowe SW.

Cancer Discov. 2019 Jul;9(7):962-979. doi: 10.1158/2159-8290.CD-18-1391. Epub 2019 May 8.

PMID:
31068365
12.

Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.

Park DE, Cheng J, Berrios C, Montero J, Cortés-Cros M, Ferretti S, Arora R, Tillgren ML, Gokhale PC, DeCaprio JA.

Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):1027-1032. doi: 10.1073/pnas.1818798116. Epub 2018 Dec 31.

14.

p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins.

Böhlig L, Friedrich M, Engeland K.

Nucleic Acids Res. 2011 Jan;39(2):440-53. doi: 10.1093/nar/gkq796. Epub 2010 Sep 10.

15.

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.

Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zöchbauer-Müller S, Zuber J, Malumbres M, Kollmann K, Sexl V.

Blood. 2015 Jan 1;125(1):90-101. doi: 10.1182/blood-2014-06-584417. Epub 2014 Oct 23. Erratum in: Blood. 2018 Aug 30;132(9):978-979.

16.

Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).

Bortolozzi R, Mattiuzzo E, Trentin L, Accordi B, Basso G, Viola G.

Biochem Pharmacol. 2018 Jul;153:230-241. doi: 10.1016/j.bcp.2018.01.050. Epub 2018 Feb 3.

PMID:
29408328
17.

microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma.

Kikkawa N, Kinoshita T, Nohata N, Hanazawa T, Yamamoto N, Fukumoto I, Chiyomaru T, Enokida H, Nakagawa M, Okamoto Y, Seki N.

Int J Oncol. 2014 Jun;44(6):2085-92. doi: 10.3892/ijo.2014.2349. Epub 2014 Mar 19.

PMID:
24647829
18.

Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.

Fang M, Simeonova I, Bardot B, Lejour V, Jaber S, Bouarich-Bourimi R, Morin A, Toledo F.

Oncogene. 2014 Mar 6;33(10):1336-9. doi: 10.1038/onc.2013.62. Epub 2013 Mar 11.

PMID:
23474762
19.

CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Tigan AS, Bellutti F, Kollmann K, Tebb G, Sexl V.

Oncogene. 2016 Jun 16;35(24):3083-91. doi: 10.1038/onc.2015.407. Epub 2015 Oct 26. Review.

PMID:
26500059
20.

MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.

Hüllein J, Słabicki M, Rosolowski M, Jethwa A, Habringer S, Tomska K, Kurilov R, Lu J, Scheinost S, Wagener R, Huang Z, Lukas M, Yavorska O, Helfrich H, Scholtysik R, Bonneau K, Tedesco D, Küppers R, Klapper W, Pott C, Stilgenbauer S, Burkhardt B, Löffler M, Trümper LH, Hummel M, Brors B, Zapatka M, Siebert R, Kreuz M, Keller U, Huber W, Zenz T.

Cancer Res. 2019 Jun 15;79(12):3125-3138. doi: 10.1158/0008-5472.CAN-18-3438. Epub 2019 Apr 18.

PMID:
31000522

Supplemental Content

Support Center